|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0144576,
umls-concept:C0185125,
umls-concept:C0201734,
umls-concept:C0205208,
umls-concept:C0205314,
umls-concept:C0205390,
umls-concept:C0442027,
umls-concept:C0524527,
umls-concept:C0679622
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-8-10
|
|
pubmed:abstractText |
To explore the pharmacokinetics (PKs) of paclitaxel and two major metabolites after three single oral administrations of a novel drinking solution and two capsule formulations in combination with cyclosporin A (CsA) in patients with advanced cancer. Moreover, the tolerability and safety of the formulations was studied. In addition, single nucleotide polymorphisms in the multidrug resistance (MDR1) gene were determined.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
635-42
|
|
pubmed:dateRevised |
2007-11-30
|
|
pubmed:meshHeading |
pubmed-meshheading:17205304-Administration, Oral,
pubmed-meshheading:17205304-Antineoplastic Agents,
pubmed-meshheading:17205304-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17205304-Capsules,
pubmed-meshheading:17205304-Chemistry, Pharmaceutical,
pubmed-meshheading:17205304-Cyclosporine,
pubmed-meshheading:17205304-Drinking,
pubmed-meshheading:17205304-Drug Administration Schedule,
pubmed-meshheading:17205304-Female,
pubmed-meshheading:17205304-Humans,
pubmed-meshheading:17205304-Infant,
pubmed-meshheading:17205304-Infant, Newborn,
pubmed-meshheading:17205304-Male,
pubmed-meshheading:17205304-Neoplasms,
pubmed-meshheading:17205304-Paclitaxel
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
|
|
pubmed:affiliation |
Division of Experimental Therapy, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, Amsterdam, The Netherlands. s.veltkamp@nki.nl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase I
|
